《新股消息》生科公司和譽開曼遞上市申請 淡馬錫GIC參投
臨牀階段生物製藥公司和譽開曼向聯交所提交主板上市申請,聯席保薦人爲摩根士丹利及摩根大通。
初步文件顯示,該公司專注於小分子腫瘤療法,目前已有14個在研項目,包括4項處於臨牀階段。和譽開曼去年錄得虧損7.06億元人民幣,較2019年的1.33億元人民幣擴大,今年首季虧損則爲1.23億元人民幣。
和譽開曼擁有不少知名投資者,包括禮來亞洲基金、貝萊德、華平投資、GIC、中金(03908.HK)、啓明創投、國藥資本及淡馬錫等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.